BioSpace News Archive

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that members of Transgene’s management and scientific team have been invited to participate at upcoming scientific conferences:

Shorla Pharma Limited, a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises.

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s management team will be presenting at the following virtual investor conferences:

U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application

Study Reveals the Utility of Cyan Fluorescence to Reliably Predict Pseudomonas, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods

Axonics Modulation Technologies, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, announced it has entered into a strategic alliance with Micro Systems Technologies, a leading manufacturer of medical microelectronics.

IN8bio, Inc. (“IN8bio” or the “Company”), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, announced a presentation on the scientific rationale and clinical basis for the use of gamma-delta T cells and the company’s Drug Resistant Immunotherapy (DRI) approach to target solid tumor cancers.

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Canadian patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig.

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development